New shot aims to cut dangerous COPD attacks

NCT ID NCT07418736

Recruiting now Disease control Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called CM326, given as a shot, in 318 people with moderate-to-severe COPD. The goal is to see if it can reduce the number of serious flare-ups over 24 to 52 weeks compared to a placebo. Participants must be at least 40 years old, have had COPD for over a year, and have had at least two flare-ups in the past.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CM326 (a lab-made antibody given as a shot)
What this could lead to: If it works, this could offer a new way to reduce serious COPD flare-ups and improve breathing for people with moderate-to-severe disease.
What could go wrong: This is an early Phase 2 trial, so results are not yet proven. The drug may not reduce flare-ups better than a placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Contacts and locations

Locations

China-Japan Friendship Hospital
RECRUITING

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.